Association Between NAT2 Polymorphisms and Prostate Cancer
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 2
Abstract
Background NAT2 enzyme involved in bioconversion of aromatic amines, heterocyclic arylamines and certain drugs into electrophilic ions that can be important initiators in tumorigenesis process. Objectives The aim of this study was to assess the possible association between NAT2 polymorphisms (857 G > A, 481 T > C, and 590 G > A) and risk of prostate cancer (PC). Methods Totally, 207 benign prostate hyperplasia (BPH) and 147 PC Iranian patients were evaluated. NAT2 genotypes were detected by restriction fragment length polymorphism (RFLP). Multiple logistic regression models were used to estimate the odds ratios for the association between presence of each genotype and developing PC. Results For NAT2 G857A, the frequency of AA and AG genotypes was lower among PC patients compared to those without it (1.01% vs. 0 and 55.88% vs. 54.55%, respectively; P = 0.7). For NAT2 T481c, the odds ratios for the association of TT and CT genotypes with PC were 0.65 and 0.55, respectively, which were not statistically significant (P = 0.5 and P = 0.09, respectively). For NAT2 G590a, both AA (11.11% vs. 12.87%) and AG (45.83% vs. 52.48%) genotypes were significantly more common among PC patients compared to BPC patients (P = 0.008). However, none of the relevant odds ratios were statistically significant (OR = 2.2, P = 0.2 and OR = 1.72, P = 0.1, respectively). Among PC patients, CT genotype of T481C caused more than 4-fold significant increase in the risk of developing advanced stages of PC. Conclusions Our study represented credible evidence that carrying G857A, G590A and T481C polymorphisms of NAT2 may not affect developing PC, its grading or invasion, but heterozygote genotype of T481C polymorphism (Rapid acetylator) can be associated with more advanced stages of cancer earlier in life. Further longitudinal studies with larger sample sizes are needed to more precisely assess the genetic risk factors of PC.
Authors and Affiliations
Mandana Hasanzad, Seyed Amir Mohsen Ziaei, Vahideh Montazeri, Mahdi Afshari, Seyed Hamid Jamaldini, Mahdieh Imani, Mahshid Sattari, Leila Hashemian, Seyed Rouhollah Kalantar Moaetamed, Mohammad Samzadeh
Keywords
Related Articles
- EP ID EP237298
- DOI 10.5812/ijcp.5716
- Views 71
- Downloads 0
Positive Peritoneal Cytology as a Predictor of Prognosis in Early Stage of Endometrioid Adenocarcinoma
Background Peritoneal cytology has been reported to be an independent risk factor for poor survival, but it is not included in the current international federation of gynecology a...
Application of Cold Atmospheric Plasma (CAP) in Cancer Therapy: A Review
Background Recently the use of cold atmospheric plasma (CAP) for the treatment of cancers called “Plasma Oncology” has gained promising results. The developments have raised the h...
Association between VDR Gene Polymorphisms (<i>rs 1544410</i>, <i>rs 7975232</i>, <i>rs 2228570</i>, <i>rs 731236</i> and <i>rs 11568820</i>) and Susceptibility to Breast Cancer in a Sample of Southeastern Iranian Population
Background Vitamin D receptor (VDR) is a key nuclear receptor that is associated with the risk and progression of breast cancer (BC). Objectives The present study investigated the...
Antioxidant Supplements and Breast Cancer: A Systematic Review and Meta-Analysis
Context: Breast cancer is the second most common type of cancer worldwide and the most frequent one among women. Some studies suggest a favorable role of antioxidants on breast cancer, but this is still controversial. O...
Applying Bioinformatic Tools for Modeling and Modifying Type II <i>E. coli</i> l-Asparginase to Present a Better Therapeutic Agent/Drug for Acute Lymphoblastic Leukemia
Background Asparginase is known to be one of the most important bedrocks of acute lymphoblastic leukemia (ALL) treatment in almost all pediatric regimens in treatment protocols. <...